Arixtra: four weeks of Tx significantly reduces DVT/PE risk in hip fracture patients.
| Published in: | Formulary Vol. 37; no. 10; pp. 505 - 506 |
|---|---|
| Format: | brief item Journal Article |
| Published: |
MJH Life Sciences
Oct2002
|
| Online Access: | View this record in EBSCOhost |